VectorB2B is a non-profit association formed in January 2019 and recognized as a Collaborative Laboratory (CoLAB) by the Portuguese public agency Fundação para a Ciência e a Tecnologia. With strong academic and industrial partners in the Portuguese health sector, VectorB2B brings together a wealth of knowledge and innovation. They specialize in drug discovery and development, offering services throughout the entire process from the lab to the bedside.

This includes drug discovery and screening, project design and implementation, pre-clinical and clinical scientific management, process development, and GMP manufacturing. VectorB2B is at the forefront of biomedical R&D, providing cost-efficient and strategic solutions for drug discovery and development. They also offer expertise in accelerating SARS-CoV-2 therapeutic, vaccine, or test development.

Additionally, VectorB2B is committed to transparency and animal welfare, endorsing the 3Rs principle in animal studies. With a network of excellent partners and a comprehensive range of services, VectorB2B is a trusted partner for clients in the biotech, pharmaceutical, and academic sectors